驱动基因阴性空间几何?驱动基因阴性指肿瘤样本中未检测到明确可靶向的驱动基因突变,分别占中美患者新发NSCLC患者的31%/31%。基于目前中美指南推荐,一线治疗驱动基因阴性NSCLC晚期患者主要依赖PD(L)-1±化疗的治疗方案,我们测算2030年用于驱动基因阴性NSCLC晚期一线治疗的免疫用药中美市场规模分别约为75亿元、180亿元。NSCLC下一代免疫治疗方案齐头并进——双(多)抗、IO+...
Source Link驱动基因阴性空间几何?驱动基因阴性指肿瘤样本中未检测到明确可靶向的驱动基因突变,分别占中美患者新发NSCLC患者的31%/31%。基于目前中美指南推荐,一线治疗驱动基因阴性NSCLC晚期患者主要依赖PD(L)-1±化疗的治疗方案,我们测算2030年用于驱动基因阴性NSCLC晚期一线治疗的免疫用药中美市场规模分别约为75亿元、180亿元。NSCLC下一代免疫治疗方案齐头并进——双(多)抗、IO+...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.